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Abstract
Background: Although the risk of developing colorectal cancer (CRC) is 2-4 times higher in case of a positive
family history, risk-adapted screening programs for family members related to CRC- patients do not exist in the
German health care system. CRC screening recommendations for persons under 55 years of age that have a
family predisposition have been published in several guidelines.
The primary aim of this study is to determine the frequency of positive family history of CRC (1st degree relatives
with CRC) among 40–54 year old persons in a general practitioner (GP) setting in Germany. Secondary aims are
to detect the frequency of occurrence of colorectal neoplasms (CRC and advanced adenomas) in 1st degree
relatives of CRC patients and to identify the variables (e.g. demographic, genetic, epigenetic and proteomic
characteristics) that are associated with it. This study also explores whether evidence-based information contributes
to informed decisions and how screening participation correlates with anxiety and (anticipated) regret.
Methods/Design: Prior to the beginning of the study, the GP team (GP and one health care assistant) in around
50 practices will be trained, and about 8,750 persons that are registered with them will be asked to complete the
“Network against colorectal cancer” questionnaire. The 10 % who are expected to have a positive family history
will then be invited to give their informed consent to participate in the study. All individuals with positive family
history will be provided with evidence-based information and prevention strategies. We plan to examine each
participant’s family history of CRC in detail and to collect information on further variables (e.g. demographics)
associated with increased risk. Additional stool and blood samples will be collected from study-participants who
decide to undergo a colonoscopy (n ~ 350) and then analyzed at the German Cancer Research Center (DKFZ)
Heidelberg to see whether further relevant variables are associated with an increased risk of CRC. One screening
list and four questionnaires will be used to collect the data, and a detailed statistical analysis plan will be
provided before the database is closed (expected to be June 30, 2015).
Discussion: It is anticipated that when persons with a family history of colorectal cancer have been provided
with professional advice by the practice team, there will be an increase in the availability of valid information
on the frequency of affected individuals and an increase in the number of persons making informed decisions.
We also expect to identify further variables that are associated with colorectal cancer. This study therefore has
translational relevance from lab to practice.
Trial registration: German Clinical Trials Register DRKS00006277
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Background
The risk of developing colorectal cancer (CRC) is 2–4
times higher in case of a family predisposition [1, 2]. A
repeat occurrence within a family can be noted in
around 30 % of all cases of CRC, whereby around 5 %
of these are associated with hereditary types of CRC.
The family predisposition for the remaining ~25 % of
cases has not yet been properly explained [3]. The dif-
ferent constellations of risk are currently not taken
into account in the directives of the German Federal
Joint Committee on cancer screening [4]. In 2013, the
usefulness of colorectal cancer screening for persons
under 55 years of age with a family predisposition was
declared by the IQWIG to be uncertain, as no high
quality studies could be identified in which compre-
hensive screening strategies in the general population
had been analyzed using anamnestic instruments [5].
The “Network against colorectal cancer” questionnaire
has shown that information on a positive family history
is partly overstated when patients fill in questionnaires
themselves, as opposed to when they are personally
interviewed, and that when findings are positive, only
40 % of those concerned inform their GP or gastro-
enterologist [6]. In two current reviews, the role of the GP
and other medical personnel is described as being the most
important factor influencing the decision to participate in
screening examinations [7, 8], and as having a greater influ-
ence than written invitations [8]. As around 92 % of the
German general population have a GP [9] and around 89 %
annually make use of outpatient services [10], screening
participation rates are expected to be high. The “European
Guideline for Quality Assurance in CRC screening and
diagnosis” recommends that patients should be spoken to
personally [11]. This is easy for the GP to do on account of
the trusting relationship he has with his patients.
In view of the new law on the further development
of cancer screening, as well as further clarification
demanded by the German Federal Joint Committee,
the proposed project could raise the awareness of the




The following primary research question will be addressed:
– What is the frequency of positive family history of
CRC (1st degree relatives with CRC) among 40–54
year old persons in a German GP setting?
Secondary research questions are:
– What is the frequency of colorectal neoplasms
(CRC and advanced adenomas) in 1st degree
relatives of CRC patients in a German GP
setting?
– What variables (e.g., demographic, genetic,
epigenetic and proteomic characteristics) are
associated with an increased risk of CRC?
– How can evidence-based information contribute to
informed decisions with respect to screening?
– How does screening participation correlate with
anxiety and regret?
Study design and setting
FRIDA.Frankfurt is a cross-sectional study in a general
practice setting. Prior to the beginning of the study, the
practice team (GP and one health care assistant (HCA))
will be briefly trained by study personnel in how to con-
duct the study in their practices. Before this session, a
list of all 40–54 year old patients who have attended the
practice within the last twelve months will be compiled
by means of the practice software. Afterwards the HCA
will contact eligible patients and complete the “Network
against colorectal cancer” questionnaire [13] (see screen-
ing list, Additional file 1) during a routine practice visit,
or per telephone.
Those who have a positive family history will then be
invited to participate in the study and to give their
informed consent to do so. With the help of study mate-
rials that are presented clearly and informatively (both
graphic and text based), the GP is expected to be able to
provide family members related to CRC patients with
adequate evidence-based information and to describe
prevention strategies. During this first practice visit we
plan to examine the participant’s family history of (colo-
rectal-) cancer in further detail, collect information on
previous CRC-screening tests, and gather information
on other variables (e.g. demographics) associated with
an increased risk of CRC (see questionnaire 1, Add-
itional file 2). Study participants with a hereditary risk of
CRC (suspected or already known) will be documented
and excluded from subsequent study-phases.
In a second practice visit within two weeks of the first,
details on anxiety, anticipated regret and reasons for or
against participation with respect to screening will be
collected before the study participants inform their GP
about their decision. Furthermore, informed decision
will be assessed using the validated instrument from
Steckelberg et al. [14]. The selected screening test (col-
onoscopy, fecal occult blood test) will be documented
(see questionnaire 2, Additional file 3).
If study participants are willing to undergo a colon-
oscopy, the GP will schedule an appointment with the
gastroenterologist, and ask the participant for a blood-
and stool-sample and to fill in an additional question-
naire (see questionnaire 3, Additional file 4). The
results of the colonoscopy will be documented from
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the gastroenterologist’s report for the GP. We will also
collect information on study participants who are not
willing to participate in CRC-screening (e.g. colonos-
copy before study participation due to a known posi-
tive family history of CRC).
Twelve weeks after the first practice visit, question-
naires asking about anxiety and regret will be sent out
by post to all persons who participate in the study (see
questionnaire 4, Additional file 5). For further details see
flow chart (Fig. 1).
Details on methods and design are laid down in the
original study protocol, which can be provided by the
corresponding author on demand.
Main practice and patient in- and exclusion criteria
Doctors at participating trial sites must work as a gen-
eral practitioner (GP or specialist in internal medicine),
provide health services to persons with German statu-
tory health insurance, have software which is capable of
detecting potentially eligible patients, and work in a
practice located in the German state of Hesse.
Participating GPs and Health Care Assistants must also
agree to the contractual obligations of the trial.
Patients must be 40–54 years of age, regularly attend
the GP’s practice (at least one contact in the last
12 months) and sign an informed consent form. A lack
of German language skills and gravidity are exclusion
criteria for patients.
Sample size calculation
As of August 2013, the “Forschungsnetzwerk Allgemein-
medizin Frankfurt” (ForN) [15] database contained ap-
proximately 100 general practices. An average-sized
practice treats about 1000 patients/quarter of which
about 25 % are 40–54 years of age. Over the course of a
year, about 250 eligible patients will attend any one prac-
tice. It is to be expected that at least 50 % of practices
(50) will participate in the study and at least 70 % of
patients will complete the questionnaire (175/practice).
The expected sample size is at least 8,750 of which
about 875 (10 %) are expected to have a positive family
history of colorectal cancer [16]. Of these, we expect
around 350 (40 %) persons to follow the invitation to
have a colonoscopy.
Recruitment, study timeline and reimbursement
The trial will be primarily conducted in general practices
in the state of Hesse. Eligible practices will be recruited
mainly through the “Forschungsnetzwerk Allgemeinme-
dizin Frankfurt” (ForN) which is a network of general
practices that have successfully conducted research pro-
jects with our Institute [15]. During an approximately
eight-month period beginning in September, 2014, about
8,750 persons attending the general practices will be
asked about their family history (see Fig. 2). As compen-
sation, recruitment practices will receive €2 per individ-
ual that is interviewed by the HCA on the basis of the
“network against colorectal cancer questionnaire” /
screening list, and €10 per individual that is counselled
by a GP, provided with the evidence-based decision aid,
and completed all questionnaires on risk-factors, anxiety,
(anticipated) regret and informed decision.
Data collection and quality assurance/avoidance of biases
and monitoring
At the practices, the HCA will contact eligible patients
and complete the “Network against colorectal cancer”
questionnaire in a screening list with them (see screen-
ing list, Additional file 1). Every document includes
information on how to fill in the form. The informed
consent forms are sent to the Institute of General Prac-
tice (IGP) via fax on the day of the participant’s visit to
the practice, and the questionnaires will later be col-
lected from the practice by a member of the study team.
Fig. 1 Flow chart of the FRIDA.Frankfurt Study
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Questionnaire 4 will be send to the study-participants by
post. If necessary, the IGP will send out a reminder to
participants after 2 weeks. All questionnaires are shown
in Additional files 2, 3, 4 and 5.
The IGP study team will ensure that all processes in
the trial comply with Good Clinical Practice (GCP)
guidelines, the legal requirements and the standard
operating procedures (SOPs) of the IGP. The patient
questionnaires, patient information brochure and in-
formed consent form will be piloted to check their
comprehensibility and applicability. During the first
visit, participating GPs and the HCA will be thoroughly
trained and provided with the information required to
conduct all steps in the study. Amongst other things,
this will include the identification of suitable patients,
help for patients in filling out the questionnaire on
socio-demographic data, and the collection of data on
those that are not willing to participate.
All information from forms (e.g. CRFs) will be trans-
ferred to the clinical study database (IBM SPSS Statis-
tics). A data check of this database will take place
according to pre-defined trial rules (range-, validity-, and
consistency- checks according to defined SOPs devel-
oped during the course of the trial and documented in
the trial master file). Follow-up enquiries resulting from
the data plausibility check will be resolved with the help
of the GP or HCA concerned.
The collection and processing of patient data will always
be conducted using the patient identification number
(Pat.-ID) pseudonym from the GP’s practice software. To
ensure high-quality data, all pseudonymization will be
conducted by the trained HCA in the GP’s practice.
For the future investigation of genetic, epigenetic and
proteomic biomarkers associated with CRC-risk, a blood
and stool sample will be taken from study-participants
that have decided to undergo a colonoscopy. The blood
and stool samples and data from questionnaires about
other risk-factors will be transferred to the German
Cancer Research Center (DKFZ) in pseudonymized form
and stored there. In addition, a qualitative and a quanti-
tative fecal occult blood test will be performed at the
DKFZ. All blood and stool samples, as well as further
data, will be anonymized at the DKFZ and stored in the
central biorepository.
Study members of the IGP will perform on-site monitor-
ing visits as frequently as necessary and record the dates of
their visits in a database (Access®). At the visits, a study
member will check the completeness and accuracy of the
data, and, if necessary, compare the data entered into the
CRFs with clinical records (source documents). Direct
access to source documents must be permitted in order to
verify that the data recorded in the CRF and other forms
are consistent with the original source data. Findings from
this review will be discussed with the GP and HCA. The
study members will stay in regular contact with the GP and
HCA and provide feedback on the course of the study.
Data collection is scheduled to be completed by
June 30, 2015.
Fig. 2 Timeline of the of the FRIDA.Frankfurt Study
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Analysis
The data collected in this study will be described in
terms of mean, standard deviation, median, minimum,
maximum and quartiles for continuous variables, while
absolute and relative frequencies will be computed for
categorical variables. Scores on the applied standardized
questionnaires will be calculated according to the user
manuals. Frequencies of positive family histories will be
reported in combination with confidence intervals.
Exploration of associated variables and group com-
parisons, e.g. in patients that have undergone or not
undergone a colonoscopy, will be performed using
logistic or linear regression models as appropriate. All
models will be adjusted for relevant confounders.
Mixed linear models will be applied in case of paired
data or repeated measures.
A detailed description of the statistical methods used
in this study will be provided in a Statistical Analysis
Plan (SAP) which will be finished before database
closure.
Ethical approval and study registration
Ethical approval for the study was obtained from the
leading Ethics Committee at the Frankfurt University
Hospital on July 8, 2014. Once the ethical approval has
been given by one ethical council in Germany, it applies
to all participating sites in the same federal state. The
study has been registered in the German Clinical Trials
Register; DRKS00006277 [17].
Discussion
In this cross-sectional study we primarily want to
investigate the frequency of positive family history of
CRC (1st degree relatives with CRC) among 40–54 year
old persons in a German GP setting. Further outcomes
are to detect the frequency of colorectal neoplasms
(CRC and advanced adenomas) in 1st degree relatives
of CRC patients and the kinds of variables that are
associated with an increased risk of CRC. In addition,
one major objective will be to measure how evidence-
based information contributes to making informed
decisions with respect to screening and how participa-
tion in screening correlates with anxiety and (antici-
pated) regret.
The role of the GP is an important factor towards
screening examinations [7, 8]. It would therefore appear
reasonable to expect data that is collected by a specially
trained and therefore highly motivated general practice
team to be of significantly higher quality. It can further
be expected that when professional advice is provided by
such a general practice team, colonoscopy participation
rates will be higher than otherwise [18], and that this, in
turn, will result in an increase in the size of the cohort
available to collect information on variables (both
demographic variables and biomarkers) for further
identification of persons with a positive medical family
history. The absence of standardized colonoscopy re-
ports from different gastroenterologists is a potential
limitation of this study. Further, variables associated with
an increased risk of CRC will be analyzed only among
1st degree relatives of CRC patients. However, this study
provides a strong translational context as it involves the
creation of new collaborations and synergies involving
GPs, clinical epidemiologists and gastroenterologists.
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